Navigation Links
Oncolytics Biotech(R) Inc. Receives Approval from Belgium FAMHP to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
Date:6/1/2010

eck cancers.

About REOLYSIN

REOLYSIN is a proprietary formulation of the human reovirus that acts primarily as a direct cytotoxic agent. Reovirus is naturally occurring (not genetically engineered) and has been demonstrated to replicate specifically in tumour cells bearing an activated Ras pathway, leaving healthy normal cells intact. At least two thirds of carcinomas and more than 90% of metastatic disease has Ras involvement.

About Oncolytics Biotech Inc.

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: www.oncolyticsbiotech.com.

This press release contains forward-looking statements, within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements, including the Company's expectations related to the FAMHP approval of a Phase 3 combination REOLYSIN and paclitaxel/carboplatin trial for patients with platinum-refractory head and neck cancers, the planned timing and implementation of the Phase 3 trial, and the Company's belief as to the potential of REOLYSIN as a cancer therapeutic, involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oncolytics Biotech(R) Inc. Announces Start of Enrolment in U.S. Phase 2 Pancreatic Cancer Clinical Trial
2. Oncolytics Biotech(R) Inc. Announces Opening of Enrollment in Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
3. Oncolytics Biotech(R) Inc. Announces Reovirus Research to be Presented at ASCO Annual Meeting
4. Oncolytics Biotech(R) Inc. Announces Phase I Colorectal Cancer Study
5. Oncolytics Biotech(R) Inc. Announces Publication of Phase I Clinical Trial Results in Clinical Cancer Research
6. Oncolytics Biotech(R) Inc. Announces First Quarter 2010 Results
7. Oncolytics Biotech(R) Inc. Announces Details of 2010 Annual Shareholder Meeting
8. Oncolytics Biotech(R) Inc. Completes Patient Enrollment in Phase I Portion of U.S. Phase I/II Recurrent Malignant Gliomas Clinical Trial
9. Oncolytics Biotech(R) Inc. Receives Approval from the U.K. MHRA to Conduct Phase 3 Trial for REOLYSIN(R) in Head and Neck Cancers
10. Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development
11. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)...  Researchers have pioneered a revolutionary new way ... called Virtual Finger, allows scientists to move through ... synapses using the flat surface of their computer ... studies orders of magnitude more efficient, saving time, ... many areas of experimental biology. The software and ...
(Date:7/10/2014)... Ohio (PRWEB) July 10, 2014 Understanding ... ion channel-expressing cell lines, and the gap that currently ... cells that expand its industry-leading portfolio of validated ion ... on ion channel-expressing cell lines, as ion channels control ... to control this activity creates the potential to treat ...
(Date:7/10/2014)... QC (PRWEB) July 10, 2014 EvoDerma ... and convenience. This rejuvenating device now comes with a second ... develops over time. , The new cup is thinner on ... design works to target rough, thin and uneven surfaces on ... firm cup for a stimulating treatment on areas such as ...
(Date:7/10/2014)... 10, 2014 /PRNewswire-iReach/ -- Tute Genomics, the ... announced an agreement with Lineagen, Inc., to ... NextStep Dx PLUS.  Lineagen, focused on ... disorders, currently offers FirstStep Dx PLUS, ... used by healthcare providers as a first-line ...
Breaking Biology Technology:Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 2Virtual Finger Enables Scientists To Navigate And Analyze 3D Images Of Complex Biological Structures 3Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 2Leader in Ion Channel Research Announces Newly Validated and Re-Engineered Cells 3Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 2Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 3Tute Genomics Platform Selected to Provide Clinical Interpretation for Lineagen's NextStepDx PLUS Next-Generation Sequencing-Based Diagnostic Test 4
... the future will utilise technologies not currently available. An ... carbon nanotubes as interconnects for computer chips. This is ... work from nanotechnology researchers within the Materials Ireland Polymer ... work to develop such junction structure nanotubes used various ...
... DIEGO, Nov. 21 Anadys Pharmaceuticals,Inc. (Nasdaq: ANDS ... 19th Annual,Piper Jaffray Healthcare Conference on Tuesday, November 27, ... is being held at the Pierre Hotel,in New York., ... of Anadys,Pharmaceuticals, Inc., will present an overview of Anadys ...
... SOUTH SAN FRANCISCO, Calif., Nov. 21 ,Exelixis, Inc. (Nasdaq: ... the company,s president and chief executive officer will present ... 1:00 p.m.,ET / 10:00 a.m. PT on Wednesday, November ... may be accessed in the Event,Calendar page under Investors ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Piper Jaffray Health Care Conference 2
(Date:7/11/2014)... "mouse TRAP" to capture the early signs of kidney ... the Journal of Clinical Investigation . Their new ... extract cellular and genetic information from a variety of ... Institute for Medical Research in 2008, TRAP involves attaching ... of the cell type of interest. Scientists can then ...
(Date:7/11/2014)... Researchers from Salk Institute for Biological Studies, BGI, ... the safety and reliability of the existing targeted ... method, TALEN-HDAdV, which could significantly increased gene-correction efficiency ... study published online in Cell Stell Cell ... cell-based gene therapy. , The combination of stem ...
(Date:7/11/2014)... two different ways that allow unprecedented experimental insights ... of oxygen molecules in photosynthesis. The two studies ... Nature Communications . , "The new knowledge will ... oxidation, which are key components for building artificial ... energy in fuels like hydrogen, ethanol or methanol," ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2Molecular snapshots of oxygen formation in photosynthesis 2
... Mass., Sept. 4, 2008 Declaring the success of ... philanthropists Eli and Edythe Broad announced today that they ... of Harvard and MIT to $600 million. Adding to ... gave an endowment of $400 million to convert the ...
... and New South Wales have put aside their competitive ... project, as announced by Innovation Minister Gavin Jennings and ... today. Scientists from the Monash Institute of ... will compare two different methods of creating patient-specific stem ...
... University of Texas Medical Branch at Galveston researchers have discovered ... Ebola Zaire virus infects cells a critical step to ... the virus. Ebola produces severe and often fatal hemorrhagic ... 90 percent in some outbreaks. No vaccine or antiviral therapy ...
Cached Biology News:Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 2Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 3Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 4Eli and Edythe L. Broad make unprecedented gift to endow Broad Institute of Harvard & MIT 5Stem cell research puts interstate rivalry on hold 2Scientists uncover Ebola cell-invasion strategy 2
... of Taq DNA polymerase. It is a ... Expressed from a gene construct in E. ... 5'-3' exonuclease domain of the DNA polymerase-encoding ... and even more heat-stable DNA polymerase activity ...
... (ELISA) test kits are qualitative one-step kits ... of drugs and/or their metabolites in forensic ... use only. It is recommended that all ... method such as GC/MS. The simple ...
... inhibitor that noncovalently binds and inactivates neutral pancreatic ... RNase 1, T1, T2, H, U1, U2 or ... inhibitor in that it has a more robust ... RNase in the absence of DTT or other ...
...
Biology Products: